Article citationsMore>>
Zer, A., Ahn, M., Barlesi, F., Bubendorf, L., De Ruysscher, D., Garrido, P., et al. (2025) Early and Locally Advanced Non-Small-Cell Lung Cancer: ESMO Clinical Practice Guideline for Diagnosis, Treatment and Follow-Up. Annals of Oncology, 36, 1245-1262.
https://doi.org/10.1016/j.annonc.2025.08.003
has been cited by the following article:
-
TITLE:
Complete Response in Inoperable Stage IIB Squamous Cell Lung Carcinoma after Sequential Radiotherapy and Chemotherapy: A Case Report and Review of the Literature
AUTHORS:
Gyursen Ziyafetova
KEYWORDS:
Non-Small Cell Lung Cancer, Chemotherapy, Radiotherapy
JOURNAL NAME:
Advances in Lung Cancer,
Vol.15 No.1,
March
19,
2026
ABSTRACT: Background: This manuscript reports a stage IIB (cT3N0M0) squamous NSCLC case deemed inoperable and treated with definitive radiotherapy followed by carboplatin/paclitaxel, achieving complete metabolic response on PET/CT. The paper then reviews standard management options for stage II NSCLC, emphasizing multidisciplinary decision-making. The main message is that selected inoperable stage II patients may achieve durable control with sequential or concurrent chemoradiation. Patients and Methods: I present a case report of complete therapeutic response in inoperable stage IIB non-small cell lung carcinoma after sequential radiotherapy and chemotherapy and a review of literature. Results: Surgical resection is the cornerstone of treatment and the best option for achieving cure in patients with clinically operable Non-Small Cell Lung Cancer (NSCLC). In circumstances where surgical resection may not be feasible, patients may be presented at a Multidisciplinary Tumour Board for further discussion between surgery, medical oncology, radiation oncology, and palliative care. Whenever possible, patients should be considered for enrollment in clinical trials. Conclusions: Patients with stage II NSCLC who are inoperable or refuse surgery can also have long survival with concurrent or sequential radiotherapy and chemotherapy.